Posts by: Joana Carvalho

News

Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a faster and easier treatment for people with multiple ... Read more

July 8, 2019

FDA Approves Xpovio Combo for Heavily Treated RRMM Patients

News

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid dexamethasone, for the treatment of adults with relapsed ... Read more

July 3, 2019

Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says

News

Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new therapeutic targets for the disease, ... Read more

July 1, 2019

FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid (lenalidomide) and dexamethasone, to treat patients newly diagnosed with multiple myeloma who ... Read more

June 26, 2019

Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma

News

Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with relapsed or refractory multiple myeloma who received at ... Read more

June 19, 2019

CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows

News

CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple myeloma, including those who relapsed after receiving ... Read more

June 17, 2019

Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show

News

Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from Phase 1/2 trials ... Read more

June 5, 2019

FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab) in combination with standard pre-transplant therapy for the treatment ... Read more

May 24, 2019

Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma

News

Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory ... Read more

May 8, 2019

Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model

News

ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and anti-tumor activity after large-scale manufacturing, a study ... Read more

Posts by: Joana Carvalho

Joana Carvalho

Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA

FDA Approves Xpovio Combo for Heavily Treated RRMM Patients

Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says

FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma

Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma

CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows

Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show

FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients

Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma

Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model

Pin It on Pinterest